Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sergliflozin
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sergliflozin (GW869682) is an investigational small molecule drug that acts as a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Its mechanism of action involves blocking SGLT2 in the renal proximal tubules, thereby reducing glucose reabsorption and promoting urinary glucose excretion. This leads to lower blood glucose levels and potential weight loss due to caloric loss through glycosuria. Sergliflozin was developed primarily for the treatment of type 2 diabetes mellitus and obesity. Clinical studies have evaluated its effects on weight loss, body composition changes, food intake, urine glucose excretion in obese subjects, and safety/tolerability in patients with type 2 diabetes[1][3][4][5][7]. The drug was developed by GSK.
- Other names
- sergliflozinGW869682GW-869682GW 869682
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on Sergliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sergliflozin.